The American pharmaceutical company Moderna has applied to the FDA for emergency use permission for a vaccine that corresponds to the Omicron strain "BA.4" and "BA.5" in the new coronavirus mutant virus. announced.
Pfizer, a major pharmaceutical company, has also applied for a vaccine for the Omicron strain, and pharmaceutical companies are moving one after another in anticipation of vaccination after autumn.
Moderna announced today that it has submitted an application to the FDA seeking emergency use authorization for its vaccine for the Omicron strain of the novel coronavirus.
The vaccine is a type called "bivalent vaccine" that contains two types of components, one corresponding to the Omicron strain "BA.4" and "BA.5" and the other corresponding to the conventional new coronavirus, and is suitable for people aged 18 and over. We applied for additional inoculation of this.
Moderna is currently in clinical trials of the vaccine, and is preparing to ship the vaccine in September if FDA approval is obtained.
This application for Moderna follows the application by major pharmaceutical companies such as Pfizer announced on the 22nd, and in the United States, pharmaceutical companies are moving one after another in anticipation of additional vaccinations after autumn.